Insider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells 7,154 Shares of Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 7,154 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $32.84, for a total value of $234,937.36. Following the transaction, the executive vice president now owns 45,670 shares of the company’s stock, valued at $1,499,802.80. This represents a 13.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Eric Swayze also recently made the following trade(s):

• On Tuesday, November 12th, Eric Swayze sold 1,194 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $37.92, for a total transaction of $45,276.48.

Ionis Pharmaceuticals Stock Down 2.6 %

IONS stock opened at $31.43 on Friday. The firm has a market cap of $4.96 billion, a PE ratio of -12.88 and a beta of 0.35. Ionis Pharmaceuticals, Inc. has a 12 month low of $31.40 and a 12 month high of $52.49. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. The firm has a 50 day simple moving average of $35.63 and a 200 day simple moving average of $41.17.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC raised its position in shares of Ionis Pharmaceuticals by 222.5% during the fourth quarter. SG Americas Securities LLC now owns 23,927 shares of the company’s stock worth $836,000 after purchasing an additional 16,508 shares during the period. Assenagon Asset Management S.A. lifted its stake in Ionis Pharmaceuticals by 967.2% during the fourth quarter. Assenagon Asset Management S.A. now owns 141,917 shares of the company’s stock valued at $4,961,000 after buying an additional 128,619 shares in the last quarter. Everence Capital Management Inc. purchased a new stake in Ionis Pharmaceuticals during the fourth quarter valued at about $237,000. Geode Capital Management LLC boosted its holdings in shares of Ionis Pharmaceuticals by 7.4% in the third quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company’s stock worth $106,922,000 after buying an additional 183,814 shares during the period. Finally, Public Employees Retirement System of Ohio increased its position in shares of Ionis Pharmaceuticals by 2.8% in the third quarter. Public Employees Retirement System of Ohio now owns 56,825 shares of the company’s stock worth $2,276,000 after acquiring an additional 1,529 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on IONS shares. Wells Fargo & Company cut their price objective on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th. William Blair reaffirmed an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Guggenheim decreased their price objective on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. Piper Sandler cut their target price on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a research note on Wednesday. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Ionis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.65.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.